Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Edward Paule who wrote (8610)	2/3/1999 6:04:00 PM
From: aknahow	Respond to of 17367

I hope not, but don't know how it will react to good news. IMO there are some major pluses for XOMA. It owns 100% of Neuprex. One hardly has an idea of what a company that has partnered owns of any drug they might have developed. Not only is the current trial a sepsis proxy, success will tend to validate the BPI platform. I think some of us would welcome a yawn from the market as it would provide a chance to add to existing positions. After all if we were willing to hold it before approval do you think many of us will not like it even more after approval? Those who like it are not doing so out of love for a stock that has great momentum. Even so there probably will be some selling on good news by those who don't like it and have just held trying to get even. It is also logical that once approval comes other news will follow, such as partnerships negotiated from strength not weakness. For years XOMA has been panned for not having partners, but now IMO this will be a big advantage, if the trial is a success.